Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model

Binder, Pratibha

158
Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

P. S. Binder¹, S. P. Goedegebuure¹, M. C. Hornick¹, D. Spitzer¹, M. A. Powell², D. G. Mutch² and W. Hawkins²
¹Washington University School of Medicine, St Louis, MO, ²Washington University School of Medicine, St. Louis, MO

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

158
Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model

158 Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model

158
Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model